ExtendicareTSX:EXE +3.63%81 EBITDA Margin % is 13.87% as of Mar. 2026, which is 58% above its 10-year median of 8.77. GuruFocus rates TSX:EXE with a GF Score™ of 81/100 and a GF Value™ of C$13.93 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 668 Healthcare Providers & Services companies, Extendicare ranks better than 56.44% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Extendicare's EBITDA for the
three
months ended in Mar. 2026 was C$65 Mil. Extendicare's Revenue for the
three
months ended in Mar. 2026 was C$465 Mil. Therefore, Extendicare's EBITDA margin for the quarter that ended in Mar. 2026 was 13.87%.
Extendicare (TSX:EXE) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Extendicare EBITDA Margin % Related Terms
Extendicare EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Extendicare's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSX:EXE vs HCA, THC, DVA: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Extendicare's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Extendicare EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Extendicare's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Extendicare's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Extendicare (TSX:EXE) has a EBITDA Margin % of 13.87% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Extendicare and its competitors. This is 58% above median its historical median of 8.77. Over the past decade, Extendicare's EBITDA Margin % has ranged from 4.05 to 12.52. According to the industry distribution chart, Extendicare ranks #291 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 43.6%.
Is Extendicare's EBITDA Margin % too high?
Extendicare's current EBITDA Margin % of 13.87% is 58% above median its 10-year median of 8.77. Over the past 10 years, this metric has ranged from a low of 4.05 to a high of 12.52. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. Extendicare's value of 13.87% is 35.8% above this industry median. Based on the distribution chart, Extendicare ranks #291 out of 668 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Extendicare has a GF Score™ of 81/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Extendicare's EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Extendicare ranks #291 out of 668 companies for EBITDA Margin %. This puts Extendicare in the upper half of its industry. The industry median EBITDA Margin % is 10.21. Extendicare's value of 13.87% is 35.8% above this benchmark. Historically, Extendicare's own EBITDA Margin % has ranged from 4.05 to 12.52 over the past decade. While the company's 10-year median is 8.77 vs. the industry median of 10.21, Extendicare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Extendicare's current EBITDA Margin % of 13.87% is 35.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Extendicare and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Extendicare's current EBITDA Margin % is 13.87%, which is 58% above median its own 10-year median of 8.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Extendicare stock overvalued right now?
Based on GuruFocus' analysis, Extendicare (TSX:EXE) is currently considered Significantly Overvalued. The stock's GF Value™ is C$13.93, compared to a current price of C$35.37 — trading 153.9% above its estimated fair value. The current EBITDA Margin % is 13.87%, which is 58% above median its 10-year median of 8.77 and 35.8% above the Healthcare Providers & Services industry median of 10.21. Extendicare's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Extendicare (TSX:EXE), the current EBITDA Margin % is 13.87% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Extendicare (TSX:EXE) Overvalued in 2026?
Based on GuruFocus' analysis, Extendicare stock appears to be overvalued.
The current stock price of C$35.37 is trading 153.9% above its estimated GF Value™ of C$13.93.
GuruFocus considers Extendicare to be Significantly Overvalued.
Key valuation signals for TSX:EXE:
EBITDA Margin %: 13.87% (58% above median its 10-year median of 8.77)
GF Value™: C$13.93 vs. price of C$35.37 (153.9% above fair value)
Industry Position: 35.8% above the Healthcare Providers & Services median (#291 of 668)
No single metric tells the full story. See the TSX:EXE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Extendicare Inc is a senior care provider in Canada, focused on long-term care and home health care. The has three main business segments: Long-term Care (LTC), Home Health Care, and Managed Services. The Long-term Care segment, operating under the Extendicare brand, represents 53 owned homes in Ontario, Alberta and Manitoba. The Home Health Care segment, operating under the ParaMed brand, provides home health care services annually in Ontario, Alberta, Manitoba and Nova Scotia. The Managed Services segment, operating under the Extendicare Assist and SGP Purchasing Partner Network brands, provides management, consulting and group purchasing services to other care providers across Canada. The majority of the company's revenue is derived from the Long-term Care segment.
81GF Score
Get the complete analysis for TSX:EXE
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:EXE has been successfully added to your 
